

Male				
	Treatment Groups (mg/kg)			
	17 ^a	35 ^a	140 ^a	17 IV ^b
	Plasma			
C ₀ min(pred) (ug/mL)				10.5 ± 1.2
C _{max} (ug/mL) *	0.192 ± 0.022	1.02 ± 0.41	2.06 ± 0.73	
T _{max} (minute)	10	20	20	
Alpha (min ⁻¹)				0.0869 ± 0.0064
t _{1/2} (Alpha) (minute)				7.98 ± 0.59
Beta (min ⁻¹)				0.0100 ± 0.0009
t _{1/2} (Beta) (minute)				69.1 ± 6.2
Cl (mL/min/kg)				110 ± 2
Cl _{1(F)} (mL/min/kg)	1062 ± 74	755 ± 65	499 ± 35	
V ₁ (L/kg)				11.0 ± 1.0
AUC _{0-t} (ug/mL*min)	16.0 ± 1.1	92.7 ± 8.0	280 ± 19	131 ± 3
AUC _{inf} (ug/mL*min)				146 ± 10
F (percent)	17.0 ± 2.0			

Experiment Number: K10262
Route: Gavage, IV
Species/Strain: Rat/Fischer 344/N

Toxicokinetics Data Summary
Test Compound: Isoeugenol
CAS Number: 97-54-1

Date Report Requested: 11/09/2016
Time Report Requested: 14:03:39
Lab: Battelle Northwest Laboratory

Female							
	Treatment Groups (mg/kg)						
	17 ^a		35 ^a		140 ^a		
					17 IV ^b		
Plasma							
C ₀ min(pred) (ug/mL)						10.6	± 0.9
C _{max} (ug/mL) *	0.364 ± 0.103		1.82 ± 0.88		5.91 ± 2.28		
T _{max} (minute)	10		2		5		
Alpha (min ⁻¹)						0.0920	± 0.0052
t _{1/2} (Alpha) (minute)						7.54	± 0.42
Beta (min ⁻¹)						0.00872 ± 0.00044	
t _{1/2} (Beta) (minute)						79.5	± 4.1
Cl (mL/min/kg)						105	± 2
Cl _{1(F)} (mL/min/kg)	564 ± 53		455 ± 29		339 ± 13		
V ₁ (L/kg)						12.0	± 0.7
AUC _{0-t} (ug/mL*min)	30.1 ± 2.8		154 ± 10		413 ± 16		
AUC _{inf} (ug/mL*min)						139	± 3
F (percent)	11.0 ± 2.0						
						156	± 7

Experiment Number: K10262
Route: Gavage, IV
Species/Strain: Rat/Fischer 344/N

Toxicokinetics Data Summary
Test Compound: Isoeugenol
CAS Number: 97-54-1

Date Report Requested: 11/09/2016
Time Report Requested: 14:03:39
Lab: Battelle Northwest Laboratory

LEGEND

Data are displayed as mean \pm SEM

* Data are displayed as mean \pm SD

MODELING METHOD & BEST FIT MODEL

^a Manual; Plasma MEG concentration-versus-time profiles for both species were characterized by an early absorption phase followed by at least one secondary peak which prevented estimation of elimination rates. No modeling was done on the oral gavage data. Parameters were calculated using observed values.

^b Nonlinear least-squares fitting program SAS PROC NLIN, SAS Institute, Inc., Cary, NC; Elimination of IEG was modeled for both species using a biphasic exponential equation $C(t) = Aoe^{-\alpha t} + Boe^{-\beta t}$ where $C(t)$ is the plasma IEG concentration at any post-administration time (t), α and β are the rate constants (min^{-1}) obtained from the fit, Ao and Bo are the intercepts on the ordinate (concentration) axis of the extrapolated initial and terminal phases, respectively. weighting factor of [mean plasma IEG concentration]⁻².

ANALYTE

Isoeugenol

TK PARAMETERS

$C_{0\text{min(pred)}}$ = Fitted plasma concentration at time zero (IV only)

C_{max} = Observed or Predicted Maximum plasma (or tissue) concentration

T_{max} = Time at which C_{max} predicted or observed occurs

α = Hybrid rate constant of the alpha phase

$t_{1/2(\alpha)}$ = Half-life for the alpha phase

β = Hybrid rate constant of the beta phase

$t_{1/2(\beta)}$ = Half-life for the beta phase

Cl = Clearance, includes total clearance

$Cl_{1(F)}$ = Apparent clearance of the central compartment, also $Cl_{(F)}$ for gavage groups in non-compartmental model

V_1 = Volume of distribution of the central compartment, includes V_d and V_{volume} of distribution, V_z apparent volume of distribution NCA, V_{app} apparent volume of distribution for intravenous studies

AUC_{0-t} = Area under the plasma concentration versus time curve, AUC, from time t_i (initial) to t_f (final), AUC_{last}

AUC_{inf} = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

**** END OF REPORT ****